Ovarian Cancer
Modified coxsackie-adenovirus receptor increases adenoviral transgene expression
Published in Gene Therapy Weekly, April 10th, 2003
According to a study from Finland, "an important determinant of gene transfer efficacy with adenoviral vectors is expression of the primary receptor, the coxsackie-adenovirus receptor. Unfortunately, expression may often be low in advanced clinical cancers, including ovarian, colorectal, lung, prostate, and breast cancer."
"In this study we investigated the feasibility of increasing transgene expression by incubating ovarian cancer cells with various agents and then performing transgene expression analysis," wrote A. Hemminki and coauthors, University of Helsinki,...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2003-04-10)
More Articles from Gene Therapy Weekly
- Cancer Therapy
Interleukin-12 gene therapy is a viable alternative for treating thyroid cancer - Type 1 Diabetes
Gene therapy prevents diabetic recurrence after islet cell transplantation - Colon Cancer
Cisplatin resistance could be defeated with gene targeting - Liver Therapy
A new technique uses gene transfer to improve liver cell transplantation - Ophthalmology
Ocular injection of pseudotyped adenoviral vectors could prevent blindness - Respiratory Disease
Sodium caprate enhances DEAE dextran-mediated gene delivery to the lungs - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
